Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2O5WA
|
|||
| Drug Name |
ALXN2030
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Phase 1 | [1] | |
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Complement C3 messenger RNA (C3 mRNA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05501717) A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Subcutaneous ALXN2030 in Healthy Participants. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Alexion | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.